Effects of finasteride on prostate volume and prostate-specific antigen

Journal of the Chinese Medical Association

Volumn 67, Issue 11, 2004, Pages 571-574

  Chiu, Kun Yuan ^a,b,c   Yong, Chi Rei ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^c NATIONAL CHI NAN UNIVERSITY   (Taiwan)

Author keywords

5 reductase inhibitor; Benign prostatic hyperplasia; Prostate; Prostate specific antigen

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; AWARENESS; CALCULATION; CANCER DIAGNOSIS; CLINICAL PRACTICE; CONTROLLED STUDY; DENSITY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG MECHANISM; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRESCRIPTION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; STUDENT T TEST; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 13444280440     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Brawer MK. Prostate-specific antigen: a review. Acta Onco 1991;30:161-8.
2. Oesterling JE. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
3. Stamey TA, Vang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adnocarcinoma of the prostate. N Engl J Med 1987;317; 909-16.
4. Cooper WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen. J Urol 1990;143:1146-52.
5. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate-specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-6.
6. Peters DH, Sorkin EM. Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993; 46:177-208.
7. Bruskewitz RC. Benign prostatic hyperplasia: drug and nondrug therapies. Geriatrics 1992;47:39-45.
8. Tammela TLJ, Kontturi MJ. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J Urol 1993;149:342-4.
9. Kirby RS, Vale J, Bryan J, Holmes K, Webb JA. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study. Eur Urol 1993;24:20-6.
10. Chueh SC, Yu HJ, Chiu TY, Huang CY, Lai MK. Treating benign prostatic hyperplasia with finasteride in Chinese men: 1-year experience. J Formos Med Assoc 1996;95:650-2.
11. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinly J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplaisa. N Engl J Med 1992; 327:1185-91.
12. Guess A, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993;22:31-7.
13. Presti JC, Fair WR, Andriole G, Sogoni PC, Seidmon EJ, Ferguson D, et al. Multi-center, randomized, double-blind, placebo-controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992;148: 1201-4.
14. Speakman MJ. Who should be treated and how? Evidence-based medicine in symptomatic BPH. Eur Urol 1999;36: 40-51.
15. Vaughan ED Jr. Medical management of benign prostatic hyperplasia: are 2 drugs better than one? N Engl J Med 2003; 349:2449-51.
16. Wu TT, Lee YH, Jiaan BP, Huang JK. The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia. J Chin Med Assoc 1995;56:399-403.
17. Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, et al. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. J Urol 2000;56:610-6.
18. Pannek J, Marks LS, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, et al. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1998;159:449-53.
19. Guess HA, Gormley GJ, Stoner E, Oesterling JET. The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996;155:3-9.
20. Gormley GJ, Stoner E, NG J, Guess H, Cook T, Walsh P. Effect of finasteride on prostate-specific antigen density. Urology 1994;43:53-8.
21. Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, et al. Proscar long-term efficacy and safety study. The Pless Study Group. J Urol 1999;54:670-8.
22. Cooner WH. Effect of finasteride on prostate-specific antigen density. Urology 1994;43:58-9.